Shorla Oncology^® Announces US FDA Approval of Larger Vial Size for Nelarabine Intravenous Administration for the Treatment of T Cell Acute Lymphoblastic Leukemia and T Cell Lymphoblastic Lymphoma

Shorla Oncology announced that the US FDA has approved the company’s oncology drug, Nelarabine Injection, in a larger vial size, 375mg/75mL, for adult and pediatric patients with T cell acute lymphoblastic leukemia and T cell lymphoblastic lymphoma.